| Code | CSB-RA003995MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to pozelimab, targeting the complement component 5 (C5) protein. C5 plays a central role in the complement cascade, a critical component of the innate immune system. Upon activation, C5 is cleaved into C5a and C5b fragments, where C5a acts as a potent anaphylatoxin promoting inflammation, while C5b initiates formation of the membrane attack complex (MAC) that can cause cell lysis. Dysregulated C5 activation is implicated in various complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and complement component 3 glomerulopathy.
Pozelimab is a humanized IgG4 monoclonal antibody that binds to C5, preventing its cleavage and subsequent downstream complement activation. This biosimilar antibody provides researchers with a valuable tool for investigating complement-mediated pathophysiology, studying C5 inhibition mechanisms, and exploring therapeutic approaches for complement-driven diseases. It supports studies examining inflammatory processes, immune-mediated tissue damage, and complement system regulation in various disease models.
There are currently no reviews for this product.